Dragon medical 10.0 portable#
Dragon medical 10.0 software#
Dragon medical 10.0 trial#

Hancock Health moves clinical documentation to the cloud for greater mobility, accuracy, and efficiency (pdf. Open a new window)Ĭoncord Hospital increases nurse job satisfaction and documentation efficiency (pdf.

Dragon medical 10.0 portable#

Providers at Dignity Health value efficient, portable documentation experience (pdf. Open a new window)ĪI-powered speech recognition eases clinical documentation burden for Allina Health (pdf. Northern Health enhances the continuity of patient care (pdf. Open a new window)ĭragon Medical seamless integration with Cerner improves documentation quality and timeliness at LifeBridge Health (pdf. Open a new window)Įnhancing documentation at Hattiesburg Clinic (pdf. Northeastern Health System boosts performance, efficiency, and job satisfaction (pdf. Open a new window)īoston Medical Center improves clinician experience (pdf.

Tanner Health System streamlines clinical documentation with Dragon Medical One (pdf. Nuance Launches Cloud‑Based Dragon Medical One in Canada

Nuance Continues Global Expansion to Meet Growing International Demand for AI‑Powered Clinical Documentation Platform Piedmont Healthcare Improves Clinical Documentation, Physician Productivity with Nuance AI‑Powered SolutionsĬoncord Hospital Expands Rollout of Nuance Dragon Medical One to all Physicians and Ambulatory Nurses After Realizing Time Savings

Dragon medical 10.0 software#

Halifax Health Improves Physician and CDI Team Satisfaction, Productivity and Documentation Quality with Nuance’s AI-Powered Solutions Dragon NaturallySpeaking (also known as Dragon for PC, or DNS) is a speech recognition software package developed by Dragon Systems of Newton, Massachusetts, which was acquired in turn by Lernout & Hauspie Speech Products, Nuance Communications, and Microsoft.It runs on Windows personal computers. Nuance’s AI-Powered Clinical Documentation Solution Helps Advance “Joy of Johns Hopkins Medicine” Initiative Nuance Brings Virtual Assistant Technology to 300,000 Dragon Medical One Cloud Users Wolters Kluwer Provides Voice‑Enabled Search Powered by Nuance Dragon Medical One to Millions of Clinicians Using Leading Clinical Decision Support ©2021 American Association for Cancer Research.Nuance and athenahealth Expand Strategic Collaboration to Reduce Cognitive Burden on Physicians and Care Teams and Improve the Patient Experience (Open a new window) Biomarker correlative analyses demonstrated evidence of clear dose-dependent target engagement by etigilimab.Įtigilimab had an acceptable safety profile with preliminary evidence of clinical benefit alone and in combination with nivolumab and warrants further investigation in clinical trials. Median progression-free survival was 56.0 days (Phase 1a) and 57.5 days (Phase 1b). In Phase 1b, 1 patient had a partial response 1 patient had prolonged stable disease of nearly 8 months. In Phase 1a, 7 patients (30.0%) had stable disease. Six patients experienced Grade ≥3 treatment-related AEs. The most commonly reported adverse events (AE) were rash (43.5%), nausea (34.8%), and fatigue (30.4%) in Phase 1a and decreased appetite (50.0%), nausea (50.0%), and rash (40%) in Phase 1b.

MTD for single and combination therapy was not determined maximum administered dose was 20 mg/kg. There were no dose-limiting toxicities (DLT). Thirty-three patients were enrolled (Phase 1a, n = 23 Phase 1b, n = 10). Primary objective was safety and tolerability. Using 3 + 3 design, patients underwent 14-day treatment cycles with anti-TIGIT antibody etigilimab alone (Phase 1a 0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously) or in combination with anti-PD-1 antibody nivolumab (Phase 1b 3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab).

Dragon medical 10.0 trial#

This Phase 1a/b trial was a first-in-human, open-label, multicenter, dose-escalation and -expansion study in patients with locally advanced or metastatic solid tumors. Targeting TIGIT with or without PD-1/PD-L1 checkpoint inhibition may enhance antitumor immunity. TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) is a co-inhibitory receptor of T-cell and natural killer cell activity.